July 18, 2022
PAR-22-216 - NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Cancer Institute (NCI)
The purpose of this Notice is to correct the Application Date Date matrix under Key Dates in PAR-22-216 - NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional).
The following section of PAR-22-216 has been corrected:
Part 1. Overview Information, Key Dates
Currently, it reads:
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
October 10, 2022 |
Not Applicable |
November 01, 2022 |
March 2023 |
May 2023 |
July 2023 |
|
February 13, 2023 |
Not Applicable |
March 01, 2023 |
July 2023 |
October 2023 |
December 2023 |
|
June 12, 2023 |
Not Applicable |
July 01, 2023 |
November 2023 |
January 2024 |
April 2024 |
|
October 10, 2023 |
Not Applicable |
November 01, 2023 |
March 2024 |
May 2024 |
July 2024 |
|
February 13, 2024 |
Not Applicable |
March 01, 2024 |
July 2024 |
October 2024 |
December 2024 |
|
June 12, 2024 |
Not Applicable |
July 01, 2024 |
November 2024 |
January 2025 |
April 2025 |
|
October 10, 2024 |
Not Applicable |
November 01, 2024 |
March 2025 |
May 2025 |
July 2025 |
|
February 13, 2025 |
Not Applicable |
March 01, 2025 |
July 2025 |
October 2025 |
December 2025 |
|
June 12, 2025 |
Not Applicable |
July 01, 2025 |
November 2025 |
January 2026 |
April 2026 |
Modified to read (in bold italics):
|
Application Due Dates |
Review and Award Cycles |
||||
|
New |
Renewal / Resubmission / Revision (as allowed) |
AIDS |
Scientific Merit Review |
Advisory Council Review |
Earliest Start Date |
|
October 10, 2022 |
October 10, 2022 |
November 01, 2022 |
March 2023 |
May 2023 |
July 2023 |
|
February 13, 2023 |
February 13, 2023 |
March 01, 2023 |
July 2023 |
October 2023 |
December 2023 |
|
June 12, 2023 |
June 12, 2023 |
July 01, 2023 |
November 2023 |
January 2024 |
April 2024 |
|
October 10, 2023 |
October 10, 2023 |
November 01, 2023 |
March 2024 |
May 2024 |
July 2024 |
|
February 13, 2024 |
February 13, 2024 |
March 01, 2024 |
July 2024 |
October 2024 |
December 2024 |
|
June 12, 2024 |
June 12, 2024 |
July 01, 2024 |
November 2024 |
January 2025 |
April 2025 |
|
October 10, 2024 |
October 10, 2024 |
November 01, 2024 |
March 2025 |
May 2025 |
July 2025 |
|
February 13, 2025 |
February 13, 2025 |
March 01, 2025 |
July 2025 |
October 2025 |
December 2025 |
|
June 12, 2025 |
June 12, 2025 |
July 01, 2025 |
November 2025 |
January 2026 |
April 2026 |
All other aspects of PAR-22-216 remain unchanged.
Scientific/Research Contact(s)
Morgan O'Hayre, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7482
Email: ohayrem@mail.nih.gov
Peer Review Contact(s)
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov
Financial/Grants Management Contact(s)
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov
and Human Services (HHS)
